Shire launches ADHD tech challenge

Share this article:

Taking a page from Sanofi, Shire is preparing to launch a developer challenge “to create technology driven solutions that aid individuals with ADHD during the transition from adolescence into adulthood.”

The company's two-stage Shire ADHD Transitions Challenge will shower $150,000 in awards on eight teams of developers. The overall winner will take home $100,000 and score two tickets to the Fall 2013 Health 2.0 conference, where their win will be announced.

Judges will be looking for tools that help ADHD patients manage transitions – such as those from high school to the less-structured environment of college life, or from college to the workforce – as well as addressing everyday organizational and life management challenges and encouraging medication adherence. For the first phase of the challenge (submissions are due by March 17), teams will submit a five-page plan. In the second phase, five finalist teams will execute on their plans.  

A 2007 survey suggests that almost 10% of US children and 4.4% of adults are affected by ADHD, for which Shire markets Adderall XR, Intuniv and Vyvanse.

Shire's contest is reminiscent of Sanofi's Data Design Diabetes and Collaborate | Activate challenges, for technology to help diabetes patients and patient advocacy groups, respectively.

Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...